Triple Threat: HDV, HBV, HIV Coinfection.
Yen DW, Soriano V, Barreiro P, Sherman KE.
Clin Liver Dis. 2023 Nov;27(4):955-972. doi: 10.1016/j.cld.2023.05.010. Epub 2023 Jul 1.
Hepatitis C (HCV) Agents.
[No authors listed]
2022 Feb 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.
Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines.
Chayama K, Hayes CN, Ohishi W, Kawakami Y.
J Gastroenterol. 2013 Jan;48(1):1-12. doi: 10.1007/s00535-012-0714-9. Epub 2012 Nov 28.
Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.
Ogawa E, Furusyo N, Kajiwara E, Nomura H, Kawano A, Takahashi K, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.
J Gastroenterol Hepatol. 2015 Aug;30(8):1309-16. doi: 10.1111/jgh.12945.
Management of side-effects.
Rosa I.
Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S69-74. doi: 10.1016/S2210-7401(11)70011-0.
Management of hepatitis C infection before and after liver transplantation.
Fagiuoli S, Ravasio R, Lucà MG, Baldan A, Pecere S, Vitale A, Pasulo L.
World J Gastroenterol. 2015 Apr 21;21(15):4447-56. doi: 10.3748/wjg.v21.i15.4447.
Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: a frequentist meta-analysis approach.
Lanini S, Mammone A, Puro V, Girardi E, Bruzzi P, Ippolito G.
New Microbiol. 2014 Jul;37(3):263-76. Epub 2014 Jul 1.
Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates.
Mehawej M, Rostaing L, Alric L, Del Bello A, Izopet J, Kamar N.
J Transplant. 2015;2015:159795. doi: 10.1155/2015/159795. Epub 2015 Jul 16.
The kinetics of cancer cells and of HIV1: the problems of cell and virus rebounds and of latency.
Mathé G.
Biomed Pharmacother. 1998;52(10):413-20. doi: 10.1016/S0753-3322(99)80018-3.
Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection.
Chayama K, Mitsui F, Hayes CN.
Expert Rev Gastroenterol Hepatol. 2015 Jan;9(1):21-30. doi: 10.1586/17474124.2015.960394. Epub 2014 Sep 14.
